irinotecan has been researched along with Fibrosarcoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chakravarti, S; Das, RP; Gota, V; Gurjar, M; Kunwar, A; Lakhamje, P; Patel, SS; Singh, BG | 1 |
| Chawla, S; Chmielowski, B; Dry, SM; Eckardt, MA; Eilber, FC; Higuchi, T; Hoffman, RM; Igarashi, K; Kanaya, F; Kawaguchi, K; Kiyuna, T; Li, Y; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Oshiro, H; Razmjooei, S; Russell, TA; Singh, AS; Singh, SR; Sugisawa, N; Tome, Y; Wangsiricharoen, S; Zhang, Z; Zhao, M | 1 |
| Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Urano, M | 1 |
| Adhikari, D; Banerjee, D; Bertino, JR; Fu, JZ; Schnieders, B; Zhao, SC | 1 |
| Katschinski, DM; Robins, HI | 1 |
| Furuta, T; Yokokura, T | 1 |
6 other study(ies) available for irinotecan and Fibrosarcoma
| Article | Year |
|---|---|
Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugation.
Topics: A549 Cells; Animals; Drug Carriers; Female; Fibrosarcoma; Folate Receptors, GPI-Anchored; Folic Acid; Gelatin; Half-Life; HeLa Cells; Humans; Hydrogen-Ion Concentration; Irinotecan; Mice; Nanoparticles; Particle Size; Polysorbates; Topoisomerase I Inhibitors | 2020 |
A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fibrosarcoma; Humans; Indazoles; Irinotecan; Male; Mice, Nude; Pyrimidines; Random Allocation; Salmonella Infections; Salmonella typhimurium; Sulfonamides; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.
Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Screening Assays, Antitumor; Fibrosarcoma; Gemcitabine; Hyperthermia, Induced; Irinotecan; Melphalan; Mice; Mice, Inbred C3H; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2003 |
Role of E2F-1 in chemosensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Survival; Cloning, Molecular; Culture Media, Serum-Free; DNA-Binding Proteins; Doxorubicin; E2F Transcription Factors; E2F1 Transcription Factor; Etoposide; Fibrosarcoma; Humans; Irinotecan; Paclitaxel; Recombinant Proteins; Retinoblastoma-Binding Protein 1; Tetrahydrofolate Dehydrogenase; Transcription Factor DP1; Transcription Factors; Transfection; Tumor Cells, Cultured | 1998 |
Hyperthermic modulation of SN-38-induced topoisomerase I DNA cross-linking and SN-38 cytotoxicity through altered topoisomerase I activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Division; Cell Nucleus; Cell Survival; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Fibrosarcoma; Hot Temperature; Humans; Hyperthermia, Induced; Irinotecan; Kinetics; Lung Neoplasms; Mice; Topoisomerase I Inhibitors | 1999 |
[Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Fibrosarcoma; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Leukemia L1210; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental | 1990 |